A patient on bupropion (Wellbutrin) and buspirone has insomnia despite melatonin; what next steps are recommended?

Next Steps for Insomnia in a Patient on Bupropion and Buspirone

Start cognitive behavioral therapy for insomnia (CBT-I) immediately, and if pharmacotherapy is needed, initiate a short-intermediate acting benzodiazepine receptor agonist such as zolpidem, eszopiclone, or zaleplon at the lowest dose. 1

Understanding the Problem

Your patient's insomnia is likely medication-induced or exacerbated by their current regimen. Bupropion is well-documented to cause insomnia as one of its most common adverse effects, with the highest incidence among second-generation antidepressants 2. The FDA label explicitly lists insomnia as a frequent adverse reaction requiring monitoring 3. Buspirone, despite being used for anxiety, has demonstrated stimulant rather than sedative properties in sleep studies, actually increasing wake time after sleep onset, particularly during initial administration 4.

First-Line Treatment: CBT-I

Cognitive behavioral therapy for insomnia (CBT-I) should be your initial intervention before adding more medications 5, 6. This is a strong recommendation based on moderate-quality evidence and represents the standard of care. CBT-I includes:

• Stimulus control therapy: Use bed only for sleep and sex; leave bedroom if unable to sleep within 15-20 minutes
• Sleep restriction therapy: Initially limit time in bed to match actual total sleep time (minimum 5 hours), then adjust weekly based on sleep efficiency
• Cognitive therapy: Address maladaptive beliefs about sleep (e.g., "I can't sleep without medication")
• Sleep hygiene education: Maintain consistent sleep-wake times, avoid caffeine/alcohol, limit daytime napping to 30 minutes before 2 PM 7

Sleep hygiene alone is insufficient and should never be used as monotherapy 1.

Pharmacological Options When CBT-I Is Insufficient

If CBT-I is unavailable or provides inadequate response, the recommended medication sequence is 1:

First-Line Pharmacotherapy:

Short-intermediate acting benzodiazepine receptor agonists (BzRAs) or ramelteon:

• Zolpidem 5-10 mg (5 mg for elderly): Best for sleep-onset insomnia, short-acting, minimal residual sedation
• Eszopiclone 2-3 mg (1 mg for elderly): Addresses both sleep onset and maintenance, intermediate-acting
• Zaleplon 5-10 mg: Ultra-short acting, ideal for sleep-onset only, no residual effects
• Ramelteon 8 mg: Melatonin receptor agonist, no abuse potential, good for sleep onset 1, 7

Start at the lowest available dose and match the drug's half-life to the patient's specific complaint (onset vs. maintenance insomnia) 1.

Second-Line Options:

If initial BzRA fails, try an alternate BzRA with different pharmacokinetics before moving to other classes 1.

Third-Line (If Comorbid Depression/Anxiety):

Sedating antidepressants such as:

• Trazodone 25-100 mg: Most commonly used, minimal anticholinergic effects
• Doxepin 3-6 mg: FDA-approved for insomnia at low doses
• Mirtazapine 7.5-15 mg: Highly sedating, but associated with weight gain 1

Note: Low-dose sedating antidepressants do not constitute adequate treatment for major depression 1.

Critical Caveats and Pitfalls

Avoid these common mistakes:

1. Do NOT use melatonin supplements for chronic insomnia—guidelines explicitly state insufficient efficacy and safety data 1. The patient has already tried this unsuccessfully.

2. Do NOT use OTC antihistamines (diphenhydramine, doxylamine)—not recommended due to lack of efficacy data and anticholinergic side effects 1

3. Consider medication timing: If bupropion is contributing significantly, discuss with the prescribing provider about dosing earlier in the day or switching to sustained-release formulations 3

4. Monitor for drug interactions: BzRAs can interact with other CNS depressants; educate about alcohol avoidance 1

5. Set clear expectations: Discuss treatment goals, potential side effects, rebound insomnia risk, and plan for regular follow-up every few weeks initially 1

Combining Treatments

Pharmacotherapy should be supplemented with behavioral therapies whenever possible 1. Combined therapy (CBT-I plus medication) shows no consistent advantage over CBT-I alone, but may be appropriate based on symptom severity, patient preference, and treatment availability 1.

Long-Term Management

• Use the lowest effective maintenance dose
• Consider intermittent dosing (3 nights/week) or as-needed use rather than nightly 1
• Medication tapering is facilitated by CBT-I—this is another reason to prioritize behavioral therapy 1
• Plan for regular follow-up to assess effectiveness, monitor adverse effects, and evaluate for new comorbidities 1